ExaGrid Announces New Software Version 6.0
ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced the release of software Version 6.0, which begins shipping on September 18, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005278/en/
Key features include:
New Retention Time-Lock for Ransomware Recovery
Retention Time-Lock is a revolutionary approach to protecting backup retention data to enable fast and easy recovery from ransomware.
- ExaGrid’s two-tier architecture includes a network-facing tier and a non-network-facing tier. ExaGrid alone controls the non-network-facing tier, creating a tiered air gap.
- Backups are written to the network-facing-tier for fast backup performance. The most recent backups are kept in their full undeduplicated form for fast restores.
- Data is adaptively deduplicated (for storage cost efficiency) into the non-network-facing tier for long-term retention data. Organizations can have as many days, weeks, months, or years of retention as they require. There is no limit to the number of version retention copies that can be saved.
- In addition to the long-term retention, ExaGrid offers a policy-driven approach allowing for any delete requests issued to the network-facing tier to be delayed in the non-network-facing tier for a specified number of days, so that backup data will not be deleted when a hacker takes control of the backup application or backup storage.
- If encrypted data is sent to the network-facing tier, or if any of its data is encrypted, ExaGrid’s repository is protected as all the deduplication objects are immutable because they are never modified.
ExaGrid assumes the hackers will take control of the backup application or the backup storage and will issue delete commands for all backups. ExaGrid has the only non-network-facing tiered backup storage solution (a tiered air gap) with delayed deletes and immutable deduplication objects. This unique approach ensures when a ransomware attack occurs, data can be easily recovered or VMs booted from the ExaGrid Tiered Backup Storage system. Not only can the primary storage be restored, but all retained backups remain intact.
“ExaGrid’s Version 6.0 provides our customers with a new strategy for ransomware recovery: ExaGrid’s Retention Time-Lock, which prevents hackers from deleting data stored in our system’s repository tier as all deletes are delayed by a policy setting. This unique approach allows customers to recover data in the event that the primary storage has become compromised by ransomware or malware,” said Bill Andrews, ExaGrid’s President and CEO. “Unlike other approaches, which require the purchase of an additional storage unit, our approach only requires that customers allocate 2% to 10% of additional repository storage in their existing system with an adjustable delay period, which is in line with our goal of offering the most cost-effective solutions to our customers.”
Security Enhancements (in addition to Ransomware Recovery), New UI Platform, and Other Highlights of Version 6.0
Version 6.0 includes the following security enhancements:
- New security officer role governs any changes to the Retention Time-Lock policy
- Optional Two-Factor authentication in web-based user interface using any OAUTH-TOTP app
- Additional control over SSH access
- Utilize Active Directory credentials from trusted domains to control share and user interface access
- New operator role for day to day operations reduces the need for administrator access.
- Security checklist for quick and easy implementation of best practices
- Automatic user interface logout after a period of inactivity
Version 6.0 includes the following additional features:
- User interface improvements provide intuitive details about how the ExaGrid system’s storage capacity is being utilized
- Streamlined navigation experience
- Deduplication and replication performance improvements across multiple backup applications
ExaGrid’s Unique Approach: Tiered Backup Storage
Disk-cache Landing Zone (Performance Tier)
- ExaGrid writes directly to disk for the fastest backup performance
- ExaGrid restores directly from disk for the fastest restores and VM boots
Long-term Retention Repository (Retention Tier)
- ExaGrid tiers long-term retention to a deduplicated data repository to reduce storage and resulting storage costs
Backing up to low-cost disk is fast for backups and restores, however, with longer-term retention, the amount of disk required becomes extremely expensive.
To reduce the amount of disk for long-term retention, deduplication appliances reduce the amount of storage and cost, however the deduplication is performed inline on the way to the disk which slows down backups to about one-third the performance of disk. Also, the data is only stored in deduplicated format resulting in extremely slow restores and VM boots as the data has to be reassembled, or rehydrated, for each request. In addition, deduplication appliances are scale-up storage which only adds storage capacity as data grows, resulting in backup windows that continue to grow as data grows, expensive forklift upgrades, and forced product obsolescence.
ExaGrid Tiered Backup Storage writes directly to disk for the fastest backups, and restores directly from disk for the fastest restores and VM boots. ExaGrid then tiers the long-term retention data to a deduplicated data repository to reduce the amount of retention storage and resulting cost. In addition, ExaGrid provides a scale-out architecture where appliances are simply added as data grows. Each appliance includes processor, memory, and network ports, so as data grows, all resources required are available to maintain a fixed-length backup window. This scale-out storage approach eliminates expensive forklift upgrades, and allows for mixing appliances of different sizes and models in the same scale-out system which eliminates product obsolescence while protecting IT investments up front and over time.
ExaGrid offers the best of both worlds by offering low-cost disk for the fastest backup and restore performance tiered to a deduplicated data repository for the lowest cost retention storage. The scale-out storage architecture provides a fixed-length backup window and is low cost up front and over time.
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our success stories.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inversago Pharma Continues to Rapidly Expand Its Leadership Team and Appoints Glenn D. Crater, MD, FCCP as Chief Medical Officer30.11.2020 14:00:00 CET | Press release
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Glenn D. Crater, MD, FCCP as its Chief Medical Officer. In this position, Dr. Crater will oversee the clinical development of Inversago’s lead compound for Prader-Willi syndrome, INV-101, as well as its pipeline of other peripherally-acting CB1 inverse agonists in several other indications. “The appointment of a Chief Medical Officer is an essential element of our corporate strategy as we have entered the clinical phase with our lead compound”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma. “Glenn brings a broad range of relevant experiences in all aspects of drug development and regulatory interactions and I trust he will have a strong impact on the science we develop at Inversago, helping us meet our objective: developing safe and potent inverse agonists of peripheral CB1 receptors”, added Dr. Ravenelle. “I am very excited to join Inversago a
Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a Novel Anti-Inflammatory30.11.2020 13:00:00 CET | Press release
Kinaset Therapeutics, Inc. (“Kinaset” or the “Company”), a newly-founded biopharmaceutical company, today announced a $40 million Series A financing with a blue-chip investor syndicate of 5AM Ventures, Atlas Venture, and Gimv. The Company also announced an exclusive global in-license and services agreement with Vectura Group plc (LSE: VEC) (“Vectura”) to develop and commercialize KN-002 (formerly known as VR588), a novel, inhaled small-molecule pan-JAK inhibitor, for the treatment of eosinophilic and non-eosinophilic severe asthma. A Phase 1/1b clinical trial in healthy volunteers and patients is poised to begin in the first half of 2021. Kinaset is led by an experienced management team and Board of Directors with strong backgrounds in the development of respiratory therapeutics. The company is led by Chief Executive Officer Robert Clarke (formerly Pulmatrix, AIR/Alkermes), Chief Business Officer Roger Heerman (GlaxoSmithKline, Vectura), and Chief Development Officer Frazer Morgan (Vec
Collabio Spaces by XCDS at Web Summit 2020: Discover the Benefits of Team Collaboration30.11.2020 11:00:00 CET | Press release
Shaping the future of teamwork is a difficult challenge and Collabio® Spaces by XCDS is ready to take it head on. After several years of stealth mode development, the team which includes former QuickOffice™ engineers released their alternative view on collaboration around documents and co-authoring. Their software works with the majority of popular office document formats and enables real time collaboration even without Internet connection and clouds. Collabio Spaces allows you to share access to your documents whilst keeping them exceptionally and solely on your private mobile or desktop device. The next step in the app's evolution is taking part in Web Summit — the "best technology conference on the planet", according to Forbes. Collabio Spaces team will join 100.000+ attendees, 800+ speakers and 2500+ startups on December 2-4, 2020. The team will speak about technologies behind cloudless collaboration and real time co-authoring, present our product and meet with partners. "We'll joi
Dawex Announces the Launch of the Japan Data Exchange (JDEX) to Foster a New Data Community30.11.2020 10:00:00 CET | Press release
Dawex, the leading data exchange technology company, today announced with Kanematsu Corporation and Japan Data Exchange Inc. the launch of JDEX, a Data Exchange Platform to create a large data trading community in Japan, spanning across industry, academia, and government, and contribute to the promotion of a cross-industry and cross-border data exchange environment. The platform, relying on Dawex Data Exchange technology and operated by Kanematsu, will serve the multinational trading corporation’s domestic and foreign network. JDEX platform enables the sourcing, exchange, sharing and commercialization of data products leveraging the platform's advanced features and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005371/en/ JDEX Platform - Login screen (Photo: Dawex) Emerging as a key component of the data economy, Data Exchanges are now clearly top of the agenda of an increasing number of corporations, pub
New Studies Conclude Xlear Kills and/or Deactivates SARS-CoV-230.11.2020 09:00:00 CET | Press release
New in vitro studies, led by renowned authority on respiratory diseases, conclude Xlear nasal spray is “an effective...and replicable means to deactivate SARS-CoV-2...to an undetectable amount of infectious virus.” This conclusion is “validated by two independent sets of experiments, performed by different labs, on different viral strains...” The Virucidal studies were independently funded. “The Virucidal Studies shed important light on the role Xlear can play in helping combat the COVID-19 pandemic,” said Dr. Gustavo Ferrer, who is leading the research team. State of scientific research: Nasal sprays, such as Xlear, reduce viral load in the nose, which is vital in fighting COVID-19. Research shows COVID-19 primarily infects and spreads through the upper respiratory system. By reducing viral load in the nose, nasal sprays help limit the severity and transmission of SARS-CoV-2 (COVID-19). https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2768627. Xlear’s components are ant
Northern Data AG Opens First Own Data Center in Frankfurt30.11.2020 08:58:00 CET | Press release
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87) starts operating its first data center at its Frankfurt am Main location. From December 2020, the Frankfurt location will make up part of the Company's Distributed Computing Cluster, based on its mobile high-tech data centers. This will add to the Company's worldwide network of GPU clusters, including in the Netherlands, Scandinavia and Canada. Feasibility studies (Proof of Concept) are planned at the Frankfurt site in cooperation with research and industry. Stefan Sickenberger, COO of Northern Data, explains: "High-Performance Computing has become an integral part of research and large parts of industry. Parallel processor systems and clusters are needed to process large volumes of data at high speed and with maximum stability. A key driver of success is lower energy consumption and high power efficiency. We are pleased to be working closely with our research partners on this project. We are particularly proud of our cooperation with t